Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.

Slamon DJ, Hortobagyi GN, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz SA, Barrios CH, Fernández AC, Untch M, Visco F, Perez AL, Miller M, Majumdar S, Peyrard S, Taran T, Fasching PA.

Open source

DOI: 10.1016/j.annonc.2026.10.1288
Published: 2026-10-23
Container: Ann Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.10.1288,
  title = {Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.},
  author = {Slamon DJ and  Hortobagyi GN and  Stroyakovskiy D and  Yardley DA and  Huang CS and  Crown J and  Bardia A and  Chia S and  Im SA and  Martin M and  Loi S and  Xu B and  Hurvitz SA and  Barrios CH and  Fernández AC and  Untch M and  Visco F and  Perez AL and  Miller M and  Majumdar S and  Peyrard S and  Taran T and  Fasching PA.},
  year = {2026},
  journal = {Ann Oncol},
  doi = {10.1016/j.annonc.2026.10.1288},
  url = {https://doi.org/10.1016/j.annonc.2026.10.1288}
}

RIS

TY  - JOUR
TI  - Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.
AU  - Slamon DJ
AU  -  Hortobagyi GN
AU  -  Stroyakovskiy D
AU  -  Yardley DA
AU  -  Huang CS
AU  -  Crown J
AU  -  Bardia A
AU  -  Chia S
AU  -  Im SA
AU  -  Martin M
AU  -  Loi S
AU  -  Xu B
AU  -  Hurvitz SA
AU  -  Barrios CH
AU  -  Fernández AC
AU  -  Untch M
AU  -  Visco F
AU  -  Perez AL
AU  -  Miller M
AU  -  Majumdar S
AU  -  Peyrard S
AU  -  Taran T
AU  -  Fasching PA.
PY  - 2026
JO  - Ann Oncol
DO  - 10.1016/j.annonc.2026.10.1288
UR  - https://doi.org/10.1016/j.annonc.2026.10.1288
ER  -

APA

DJ, S., GN, H., D, S., DA, Y., CS, H., J, C., A, B., S, C., SA, I., M, M., S, L., B, X., SA, H., CH, B., AC, F., M, U., F, V., AL, P., M, M., S, M., S, P., T, T., & PA., F. (2026). Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.. Ann Oncol. https://doi.org/10.1016/j.annonc.2026.10.1288

Source records

europe-pmc · retrieved 2026-11-10T13:43:30.878Z